Loading...
Back to narrative

High Consumable Demand And Regulatory Standards Will Drive Future Success

DIM logo
DIM
AnalystConsensusTarget
Not Invested
Published 07 Nov 2024

Update shared on17 Oct 2025

Fair value Increased 1.01%
Previous
AnalystConsensusTarget's Fair Value
€231.92
8.5% undervalued intrinsic discount
17 Oct
€212.20
Loading
1Y
8.3%
7D
14.1%

Analysts have modestly raised their price target for Sartorius Stedim Biotech from €229.62 to €231.92. They cited improved revenue growth and higher profit margin projections as key drivers for the adjustment.

What's in the News

  • Sartorius Stedim Biotech and Bio Usawa Biotechnology Ltd. have formed a partnership to advance Africa's biopharmaceutical industry, with a focus on affordable monoclonal antibody manufacturing and workforce training (Key Developments).
  • The new collaboration includes initiatives in research and development, technology enablement, process optimization, and analytical quality assurance for the African market (Key Developments).
  • Sartorius Stedim Biotech has confirmed its earnings guidance for fiscal 2025, projecting organic sales revenue growth of around 7%, with a forecast range of plus or minus two percentage points due to market volatility (Key Developments).

Valuation Changes

  • Consensus Analyst Price Target has risen slightly from €229.62 to €231.92.
  • Discount Rate has decreased marginally from 6.85% to 6.79%.
  • Revenue Growth estimate has increased from 10.53% to 11.04%.
  • Net Profit Margin forecast has edged up from 15.94% to 16.32%.
  • Future P/E (Price to Earnings) ratio has fallen from 45.81x to 40.32x.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.